ASPEN Trial

(Redirected from ASPEN)
Jump to: navigation, search

Low Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low LDL
High LDL

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Prognosis and Complications

Diagnosis

Laboratory Findings

Treatment

Medical Therapy

Landmark Trials

Future or Investigational Therapies

Case Studies

Case #1

ASPEN Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of ASPEN Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on ASPEN Trial

CDC on ASPEN Trial

ASPEN Trial in the news

Blogs on ASPEN Trial

Directions to Hospitals Treating Low density lipoprotein

Risk calculators and risk factors for ASPEN Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for ASPEN.

Overview

In 1905 patients with diabetes and no prior CHD, the composite/primary end-point and secondary end-points of CV mortality, fatal/non-fatal MI, revascularizations, strokes or hospitalization for angina were similar in the treatment group (atorvastatin 10 mg daily) and placebo[1].

References


Linked-in.jpg